SWITCHING INFLIXIMAB TO SUBCUTANEOUS FROM INTRAVENOUS THERAPY (SWIMSUIT) - A PROSPECTIVE, REAL-WORLD PHASE IV INTERVENTIONAL STUDY

被引：0
|
作者：
Rahmany, Sohail [1 ]
Young, David [1 ]
Moyses, Helen [2 ]
Gonclaves, Joao [3 ]
Latter, Sue [4 ]
Cummings, Fraser [1 ]
机构：
[1] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
[2] Southampton Gen Hosp, NIHR Biomed Res Unit, Southampton, Hants, England
[3] Univ Lisbon, IMed Res Inst Med, Dept Pharm, Lisbon, Portugal
[4] Univ Southampton, Sch Hlth Sci, Southampton, Hants, England
来源：
GUT | 2023年 / 72卷 / SUPPL_2期
关键词：
D O I：
10.1136/gutjnl-2023-BSG.152
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P80
引用
收藏
页码：A92 / A93
页数：2
相关论文
共 50 条
  • [1] SWITCHING INFLIXIMAB TO SUBCUTANEOUS FROM INTRAVENOUS THERAPY (SWIMSUIT) - A PROSPECTIVE, REAL-WORLD, SINGLE CENTRE, PHASE IV INTERVENTIONAL STUDY
    Rahmany, Sohail
    Young, David
    Moyses, Helen
    Goncalves, Joao
    Latter, Sue
    Cummings, Fraser
    GASTROENTEROLOGY, 2023, 164 (06) : S1121 - S1121
  • [2] Switching infliximab to subcutaneous from intravenous therapy (SWIMSUIT) - A prospective, real-world, single centre, phase IV interventional study.
    Rahmany, S.
    Young, D.
    Moyses, H.
    Gonclaves, J.
    Latter, S.
    Cummings, F.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 522 - 522
  • [3] Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations
    Ferreira, Ana Isabel
    Capela, Tiago Lima
    Arieira, Catia
    Xavier, Sofia
    Cotter, Jose
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (11) : 1314 - 1318
  • [4] CLINICAL EFFICACY AND DURABILITY OF SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER SWITCHING FROM INTRAVENOUS INFLIXIMAB: A REAL-WORLD MULTICENTER PROSPECTIVE COHORT STUDY IN KOREA
    Kim, Kyuwon
    Hong, Sung Noh
    Kang, Sang-Bum
    Lee, Kang-Moon
    Koo, Ja Seol
    Jung, Yunho
    Lee, Beom Jae
    Yoon, Hyuk
    Kim, Hyung Wook
    Lim, Yun Jeong
    Lee, Hyun Seok
    Lee, Yoo Jin
    Lee, Jun
    Lee, Chang Kyun
    Moon, Jung Min
    Shin, Seung Yong
    Seo, Jeongkuk
    Choi, Chang Hwan
    GASTROENTEROLOGY, 2024, 166 (05) : S1136 - S1136
  • [5] Long-term Efficacy and Persistence of Subcutaneous Infliximab after Switching from Intravenous Infliximab in patients with Crohn's disease: A Real-World Multicenter Prospective Cohort Study in Korea
    Kim, K.
    Hong, S. N.
    Kang, S. B.
    Lee, K. M.
    Koo, J. S.
    Jung, Y.
    Yoon, H.
    Lee, B. J.
    Lee, H. S.
    Lee, Y. J.
    Lim, Y. J.
    Lee, J.
    Lee, C. K.
    Shin, S. Y.
    Moon, J. M.
    Seo, J.
    Lim, H.
    Choi, C. H.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1466 - I1467
  • [6] Effectiveness of switching from intravenous to subcutaneous infliximab in Inflammatory Bowel Disease patients: A combined analysis of real-world evidence
    Cummings, F.
    Buisson, A.
    Smith, P. J.
    Rahmany, S.
    Subramanian, S.
    Kwon, B.
    Park, S.
    Lee, Y. N.
    Fumery, M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1332 - I1333
  • [7] EFFECTIVENESS OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: A COMBINED ANALYSIS OF REAL-WORLD EVIDENCE
    Cummings, Fraser
    Buisson, Anthony
    Smith, Philip J.
    Rahmany, Sohail
    Subramanian, Sreedhar
    Kwon, Buki
    Park, Soyeon
    Lee, Young Nam
    Fumery, Mathurin
    GASTROENTEROLOGY, 2024, 166 (05) : S1144 - S1144
  • [8] Switch from intravenous to subcutaneous maintenance infliximab in real world IBD cohort
    Mcgrory, L.
    Goess, C.
    Lynch, K.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 741 - 743
  • [9] Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
    Volkers, Adriaan
    Straatmijer, Tessa
    Duijvestein, Marjolijn
    Sales, Amber
    Levran, Amit
    van Schaik, Fiona
    Maljaars, Jeroen
    Gecse, Krisztina
    Ponsioen, Cyriel
    Grootjans, Joep
    Hanzel, Jurij
    Tack, Greetje
    Jansen, Jeroen
    Hoentjen, Frank
    de Boer, Nanne
    van der Marel, Sander
    Dijkstra, Gerard
    Oldenburg, Bas
    Lowenberg, Mark
    van der Meulen, Andrea
    D'Haens, Geert
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (06) : 1044 - 1054
  • [10] Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
    Bergqvist, Viktoria
    Holmgren, Johanna
    Klintman, Daniel
    Marsal, Jan
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (11) : 1389 - 1401
12345